Clinical Trials Logo

Clinical Trial Summary

- To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). - To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. - To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. - To determine the optimal dose and schedule of ERAS-007 monotherapy. - To evaluate antitumor activity of ERAS-007 in various solid tumors. - To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. - To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with ERAS-601. - To characterize the pharmacokinetic (PK) profile of ERAS-007 and ERAS-601 when administered in combination. - To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors - To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors


Clinical Trial Description

This is a Phase 1b/2, open-label, multicenter clinical study of ERAS-007 monotherapy (QW or BID-QW) administered either QW or BID-QWand ERAS-007 (BID-QW) in combination with ERAS-601 (BID 3/1). The monotherapy RD on a weekly schedule has been determined to be 250 mg QW in a previous study. The dose escalation phases of this study will test ERAS-007 monotherapy administered BID-QW as a monotherapy or in combination with ERAS-601 in participants with any solid tumor. The monotherapy RD on a weekly schedule has been determined to be 250 mg QW in a previous study. In parallel, the dose expansion phase of this study will test ERAS-007 monotherapy administered at the RD of 250 mg QW in participants with advanced or metastatic solid tumors harboring specific molecular alterations. Once sufficient safety and PK data are available from the BID-QW dose escalation phase, the Sponsor will then determine the optimal dose and schedule of ERAS-007 administered as a monotherapy. ;


Study Design


Related Conditions & MeSH terms

  • Advanced or Metastatic Solid Tumors
  • Neoplasms

NCT number NCT04866134
Study type Interventional
Source Erasca, Inc.
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date May 7, 2021
Completion date November 1, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05017012 - A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) Phase 1
Completed NCT02261532 - A Phase I Study of TAS-102 in Solid Tumors Phase 1
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT03248843 - A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT04003623 - Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) Phase 2
Terminated NCT05496595 - DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT01928394 - A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT01506934 - A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03730337 - Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04586270 - A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Phase 1
Recruiting NCT06248411 - A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06389526 - A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05957081 - Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 Phase 1
Active, not recruiting NCT03316638 - A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT01355302 - E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer Phase 1/Phase 2
Completed NCT01014429 - Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06074497 - A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT06448364 - A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination Phase 1